This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy?

Capricor Therapeutics (CAPR) EVP and General Counsel Karen Krasney offloaded 24,100 shares in June 2026 for approximately $732,000 through a pre-arranged 10b5-1 plan. The stock has dropped 30% year-to-date, following a 202% rally in 2025.

The sale comes ahead of a critical FDA decision on Deramiocel, the company's lead therapy, expected by August 22, 2026. The transaction was executed under a routine stock-based compensation arrangement, not a discretionary sell signal.

CAPR's sharp year-to-date decline has unwound nearly a third of last year's gains, leaving the biotech in a holding pattern as the regulatory deadline approaches. Pre-planned insider sales typically carry less weight than open-market transactions, but the timing puts focus squarely on the upcoming FDA verdict.

The August 22 date marks a binary event for the clinical-stage company. Approval could reverse the 2026 slide; rejection would likely accelerate it.